A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

NCT00211068 · clinicaltrials.gov ↗

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Pure Red-cell Aplasia

Interventions

DRUG: No intervention

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.